Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

KV Pharmaceutical Enters Consent Decree With FDA In Move To Resume Manufacturing

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Certain products will not be distributed until approved via NDA or ANDA processes.

You may also be interested in...



KV Pharmaceutical Cleared To Resume Some Drug Shipments, But Cash Crisis Looms

FDA gives go-ahead for the beleaguered company to ship two potassium chloride formulations following a satisfactory GMP inspection in August.

KV Pharmaceutical Cleared To Resume Some Drug Shipments, But Cash Crisis Looms

FDA gives go-ahead for the beleaguered company to ship two potassium chloride formulations following a satisfactory GMP inspection in August.

Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles

Firm halts manufacturing and distribution of nearly all products.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

See All
UsernamePublicRestriction

Register

PS069152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By